• Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8878451).
  

PubMed=3188836; DOI=10.1007/BF00686381
Onda K., Tanaka R., Washiyama K., Takeda N., Kumanishi T.
Correlation of DNA ploidy and morphological features of human glioma cell cultures with the establishment of cell lines.
Acta Neuropathol. 76:433-440(1988)

CLPUB00089
Onda K., Washiyama K., Tanaka R., Nishiyama A., Usui H., Kumanishi T.
GFAP-positive human glioma cell lines: no.11, no.10.
Hum. Cell 3:251-252(1990)

PubMed=8878451; DOI=10.1111/j.1349-7006.1996.tb02118.x
Zhang S., Endo S., Koga H., Ichikawa T., Feng X., Onda K., Washiyama K., Kumanishi T.
A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.
Jpn. J. Cancer Res. 87:900-907(1996)

PubMed=10551321; DOI=10.1111/j.1349-7006.1999.tb00838.x
Zhang S.-J., Endo S., Ichikawa T., Yoshimura J., Onda K., Tanaka R., Washiyama K., Kumanishi T.
Rare-type mutations of MMAC1 tumor suppressor gene in human glioma cell lines and their tumors of origin.
Jpn. J. Cancer Res. 90:934-941(1999)

PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x
Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T., Aoyagi M., Ohno K., Imoto I., Inazawa J.
Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.
Cancer Sci. 96:676-683(2005)

PubMed=18415661; DOI=10.1007/s10014-007-0226-0
Tanaka Y., Zhang S.-J., Terasaki H., Koga H., Endo S., Usui H., Washiyama K., Kumanishi T., Uematsu Y., Itakura T.
Frequent and variable abnormalities in p14 tumor suppressor gene in glioma cell lines.
Brain Tumor Pathol. 25:9-17(2008)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)